Treatment for Vulvovaginal Candidiasis (Yeast Infection)
For uncomplicated vulvovaginal candidiasis (VVC), both topical azole preparations and oral fluconazole 150 mg as a single dose are highly effective first-line treatments with cure rates of 80-90%. 1
Classification of Vulvovaginal Candidiasis
VVC can be classified into two categories which guide treatment approach:
Uncomplicated VVC (90% of cases):
- Mild-to-moderate symptoms
- Sporadic, infrequent episodes
- Likely caused by C. albicans
- In immunocompetent patients
Complicated VVC (10% of cases):
- Severe symptoms
- Recurrent episodes (≥4 episodes/year)
- Non-albicans Candida species
- Abnormal host factors (diabetes, immunosuppression, pregnancy)
Treatment Options for Uncomplicated VVC
Topical Intravaginal Agents:
Clotrimazole:
Miconazole:
Other topical options:
- Butoconazole 2% cream 5g intravaginally for 3 days 1
- Tioconazole 6.5% ointment 5g intravaginally in a single application 1
- Terconazole 0.4% cream 5g intravaginally for 7 days 1
- Terconazole 0.8% cream 5g intravaginally for 3 days 1
- Terconazole 80mg vaginal suppository, one suppository for 3 days 1
- Nystatin 100,000-unit vaginal tablet, one tablet for 14 days 1
Oral Agent:
Treatment for Complicated VVC
Severe VVC:
- Fluconazole 150mg, two sequential doses given 3 days apart 6
- OR extended duration of topical therapy (7-14 days)
Recurrent VVC:
Induction phase:
- Fluconazole 150mg every 72 hours for 3 doses (days 1,4, and 7) 1
- OR 14 days of topical therapy
Maintenance phase:
Non-albicans Candida:
Treatment Efficacy
- Single-dose oral fluconazole (150mg) is as effective as 7-day regimens of intravaginal clotrimazole, with clinical cure rates of 94% and 97% respectively at 14 days post-treatment 5
- For severe VVC, a two-dose regimen of fluconazole (150mg given 3 days apart) achieves significantly higher clinical cure rates compared to a single dose 6
- Patient preference often favors oral therapy, with 73% of patients preferring oral treatment over intravaginal options 7
Important Considerations
- Self-medication with OTC preparations should only be advised for women previously diagnosed with VVC who have a recurrence of the same symptoms 1
- Women whose symptoms persist after using an OTC preparation or who have a recurrence within 2 months should seek medical care 1
- Non-albicans Candida infections respond poorly to azole therapy and may require alternative treatments 6
- Identifying Candida by culture in the absence of symptoms should not lead to treatment, as 10-20% of women normally harbor Candida species in the vagina 1
Follow-up
- Patients should see improvement within 2-3 days of starting treatment
- If symptoms persist after completing therapy, reevaluation is necessary to confirm diagnosis and rule out other causes of vaginal symptoms